Reports Q3 revenue $3.34M, consensus $1.52M. “We are very pleased with the validating updated clinical data from our Phase 1 trials for both CUE-101 and CUE-102,” said Daniel Passeri, chief executive officer of Cue Biopharma (CUE). “Importantly, we believe the maturing data further supports and strengthens our competitive differentiation and positioning for selective modulation of disease-specific T cells. This data further bolsters our confidence that the CUE-100 series, exemplified by CUE-101 and CUE-102, represents the potential of establishing a new standard of care for cancer patients. We are also very pleased with the continued progress of our preclinical autoimmune programs, both of which have moved closer towards drug candidate selection.”
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CUE:
- Cue names Daniel Baker interim CDO, CSO Amish Suri to transition to advisor role
- CUE Upcoming Earnings Report: What to Expect?
- Cue Biopharma presents ‘positive’ update from Phase 1 trials of CUE-101, CUE-102
- Biotech Alert: Searches spiking for these stocks today
- Cue Biopharma announces pricing of $12M public offering